Capsida Biotherapeutics
A US biotech creating a new class of targeted gene therapies using its adeno-associated virus (AAV) engineering and cargo development platform.
Capsida emerged from stealth mode in May 2021 with $140 million of capital, including $90 million from AbbVie, as part of a multi-year strategic collaboration and option agreement.
In February 2023, Capsida and AbbVie announced an expansion of their strategic collaboration to develop genetic medicines for eye diseases with high unmet need.
Latest Capsida Biotherapeutics News & Features
23 February 2023
5 January 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze